RecruitingNCT07670624
T6A Biomarker for Detection of Bacterial Infection in Newborn Infants
Sponsor
Salzburger Landeskliniken
Enrollment
210 participants
Start Date
Sep 3, 2026
Study Type
OBSERVATIONAL
Conditions
Summary
This bi-center study aims to assess the efficacy of a new biomarker, N6-threonylcarbamoyladenosine (t6A), for the early diagnosis of Early-Onset Sepsis (EOS) in newborns.
Eligibility
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a new treatment for people with biomarker discovery, newborn sepsis, and other related conditions. The study is currently recruiting participants at 2 locations.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07670624
Related Trials
Development of Context-Adapted Quality Indicators for Early Sepsis Care in Sub-Saharan Africa - A Modified Delphi Consensus Procedure
NCT07711535
Efficacy and Safety of Cytokine Adsorption and Plasma Exchange in Patients With ACLF and Sepsis
NCT065628031 location
A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.
NCT0721570272 locations
Early Versus Late Adjunctive Vasopressin in Septic Shock
NCT067095731 location
Dynamic Infection Kinetics for Early Diagnosis, Monitoring, and Prognostication of Sepsis in Adult Oncology Patients: Evaluating Serial Infection Biomarkers, Blood Culture Kinetics, Treatment Response, Disease Severity, and Clinical Outcomes
NCT07795502